Home › Leukemia › NCT06487247
HEME Home Transfusion Program
Recruiting
Supportive Transfusion Program for Patients With Hematologic Malignancies: A Cluster Randomized Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria for Patient Participants: * Diagnosis of a relapsed/refractory hematologic malignancy * Age ≥ 18 years * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment) * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a severe transfusion reaction * Patient resides within catchment served by Care Dimensions Hospice * Physician-estimated prognosis of six months or less Inclusion Criteria for Caregivers: * Identified informal caregiver of enrolled patient with hematologic malignancy * Age ≥ 18 years Exclusion Criteria for Patient Participants: * Age \< 18 years * Already enrolled in hospice * Resides in nursing home or assisted living facility * History of previous serious adverse transfusion reaction Exclusion Criteria for Caregivers: -Age \< 18 years
About the study
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
What is being tested
- HEME-Hospice Program (behavioral)
Sponsor: Dana-Farber Cancer Institute · Participants: 700 · Started: Sep 10, 2025
Contact the study team
- Oreofe Odejide, MD, MPH · Phone: 617-632-6864
- Sunny Rosenthal, MPH · Phone: 857-215-2820
Official record on ClinicalTrials.gov — NCT06487247
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston Dana-Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.